7 results on '"Shimokawa, M"'
Search Results
2. A Phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer
- Author
-
Harada, T., primary, Hamada, A., additional, Shimokawa, M., additional, Takayama, K., additional, Kudoh, S., additional, Maeno, K., additional, Saeki, S., additional, Miyawaki, H., additional, Moriyama, A., additional, Nakagawa, K., additional, and Nakanishi, Y., additional
- Published
- 2013
- Full Text
- View/download PDF
3. A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Pleurectomy/Decortication Aimed at Macroscopic Complete Resection for Malignant Pleural Mesothelioma
- Author
-
Shimokawa, M., primary, Hasegawa, S., additional, Fukuoka, K., additional, Okada, M., additional, Yokoi, K., additional, Tanaka, F., additional, Yamanaka, T., additional, Daimon, T., additional, and Nakano, T., additional
- Published
- 2013
- Full Text
- View/download PDF
4. Sarcopenia and obesity in long-term survivors of childhood leukemia/lymphoma: a report from a single institution.
- Author
-
Nakayama H, Noguchi M, Fukano R, Ueda T, Taguchi S, Yoshimaru K, Namie M, Shimokawa M, and Okamura J
- Subjects
- Adolescent, Adult, Cancer Survivors, Cranial Irradiation, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia therapy, Lymphoma therapy, Male, Middle Aged, Obesity etiology, Sarcopenia etiology, Young Adult, Leukemia epidemiology, Lymphoma epidemiology, Obesity epidemiology, Sarcopenia epidemiology
- Abstract
Background: The incidence and background factors of sarcopenia and obesity in long-term survivors of childhood leukemia/lymphoma were not clear in Japan., Methods: Between August 2018 and September 2019, we recruited adults aged ≥18 years who had childhood leukemia/lymphoma. Blood sampling, body composition measurement by bioelectrical impedance analysis and grip strength test were performed., Results: Among 81 adult survivors (34 men and 47 women) with a median age of 25.0 years, 9 (11%) had sarcopenia and 10 (12%) had obesity, of whom, 3 had metabolic syndrome. Sarcopenia was observed in 7 (21%) of 33 survivors with hematopoietic stem cell transplantation (HSCT) and 2 (4%) of 48 survivors without hematopoietic stem cell transplantation (P = 0.012). The incidence of obesity was significantly higher in the cranial radiotherapy (P = 0.021) and non-transplanted cases (P = 0.042). Univariate logistic regression analysis revealed that hematopoietic stem cell transplantation for sarcopenia (odds ratio, 6.19; 95% confidence interval, 1.2-32.0; P = 0.03) and cranial radiotherapy for obesity (odds ratio, 5.6; 95% confidence interval, 1.4-22.4; P = 0.015) were significantly associated. Hypertension was more prevalent among the obese survivors, and higher transaminase levels were found more in both the sarcopenia and obese survivors than in others., Conclusions: Young adult survivors of childhood leukemia/lymphoma could be at risk of developing sarcopenia after hematopoietic stem cell transplantation and obesity after cranial radiotherapy. Further studies are required to assess the body composition of long-term survivors to find detailed risk factors of sarcopenia and metabolic syndrome., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
5. Renal function and urological complications after radical hysterectomy with postoperative radiotherapy and platinum-based chemotherapy for cervical cancer.
- Author
-
Okadome M, Saito T, Kitade S, Ariyoshi K, Shimamoto K, Kawano H, Minami K, Nakamura M, Shimokawa M, Okushima K, Kubo Y, and Kunitake N
- Subjects
- Adult, Aged, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Intraoperative Care, Middle Aged, Multivariate Analysis, Neoplasm Staging, Pelvis radiation effects, Prognosis, Propensity Score, Time Factors, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms radiotherapy, Uterine Cervical Neoplasms surgery, Hysterectomy adverse effects, Kidney physiopathology, Platinum therapeutic use, Postoperative Complications etiology, Uterine Cervical Neoplasms therapy
- Abstract
Background: We aimed to clarify renal functional changes long term and serious urological complications in women with cervical cancer who undergo radical hysterectomy followed by pelvic radiotherapy and/or platinum-based chemotherapy to treat the initial disease., Methods: Data on 380 women who underwent radical hysterectomy at the National Kyushu Cancer Center from January 1997 to December 2013 were reviewed. Main outcome measures were the estimated glomerular filtration rate (eGFR) and monitored abnormal urological findings., Results: Postoperative eGFR was significantly lower than preoperative eGFR in 179 women with surgery alone and in 201 women with additional pelvic radiotherapy and/or chemotherapy (both P < 0.01). Two types of univariate analyses for eGFR reduction in women after treatment showed that older age, advanced stage, pelvic radiotherapy, and platinum-based chemotherapy were significant variables on both analyses. Two types of multivariate analyses showed that platinum-based chemotherapy or pelvic radiotherapy were associated with impaired renal function (odds ratio 1.96, 95% confidence interval 1.08-3.54 and odds ratio 2.85, 95% confidence interval 1.12-7.24, for the respective analyses). There was a higher rate of bladder wall thickening in women with pelvic radiotherapy had than those without it (17.4% vs. 2.7%, P < 0.01). One serious urological complication (intraperitoneal rupture of the bladder) occurred among women who underwent pelvic radiotherapy (0.6% vs. 0%)., Conclusions: Surgeons should be aware that eGFR is reduced after platinum-based chemotherapy and/or postoperative pelvic radiotherapy. Serious and life-threatening urological complications are rare, but surgeons should be aware of the possibility during the long follow-up., (© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2018
- Full Text
- View/download PDF
6. Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer.
- Author
-
Arai H, Hironaka S, Minashi K, Denda T, Shimokawa M, and Yamaguchi T
- Subjects
- Adult, Aged, Aged, 80 and over, Humans, Incidence, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Stomach Neoplasms pathology, Venous Thromboembolism mortality, Venous Thromboembolism pathology, Young Adult, Stomach Neoplasms complications, Venous Thromboembolism diagnosis
- Abstract
Background: Advanced gastric cancer (AGC) and systemic chemotherapy are some of the risk factors for venous thromboembolism (VTE). However, the cumulative incidence, risk factors and prognostic impact of VTE have not been evaluated in Japanese patients with AGC., Methods: This retrospective study included patients who received fluoropyrimidine-based first-line chemotherapy for AGC between September 2009 and July 2015 at our institution. VTE was diagnosed by computed tomography scan and was managed by anticoagulant therapy. The cumulative incidence of VTE was estimated by the Kaplan-Meier method. Multivariate analysis was performed to identify the risk factors and prognostic impact of VTE., Results: Of 283 patients, 37 (13.1%) developed VTE before or during chemotherapy. The cumulative incidence of VTE was 8.7% at 6 months and 13.6% at 1 year. The independent risk factors for VTE were body mass index (BMI) of ≥25 kg/m2 (HR 3.38, 95% CI 1.72-6.65, P < 0.01) and presence of peritoneal metastasis (HR 2.01, 95% CI 1.00-4.00, P < 0.05). The median overall survival (OS) was 13.4 months for patients with VTE and 11.7 months for those without VTE (P = 0.58). After adjusting for other prognostic factors, the number of metastatic sites and metastases to the peritoneum and bone were independent prognostic factors for OS, but not for VTE (HR 0.89, 95% CI 0.62-1.28, P = 0.53)., Conclusions: BMI ≥ 25 kg/m2 and peritoneal metastasis could be the risk factors for VTE in Japanese AGC patients. VTE might have no negative impact on OS in AGC patients treated with chemotherapy., (© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
7. Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.
- Author
-
Shimada T, Saito T, Shimokawa M, Shimamoto K, Matsushita S, Yamaguchi S, Ariyoshi K, and Okadome M
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Demography, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Doxorubicin analogs & derivatives, Doxorubicin pharmacology, Doxorubicin therapeutic use, Female, Humans, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Ovarian Neoplasms pathology, Polyethylene Glycols pharmacology, Polyethylene Glycols therapeutic use, Prognosis, Gemcitabine, Molecular Targeted Therapy, Ovarian Neoplasms drug therapy
- Abstract
Objective: The prognosis of ovarian cancer has improved because of platinum- and taxane-containing chemotherapy. We investigated the 5-year disease-specific overall survival and prognostic factors of patients with advanced ovarian cancer to elucidate the change in clinical course of ovarian cancer with the advance of chemotherapy for patients who developed relapse in the era before the addition of molecular targeting therapy., Methods: We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGO Stage III and IV) treated in the past 11 years (1999-2010). We classified the patients into two groups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) and those who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year disease-specific overall survival and median survival rates between these two groups. We also investigated the prognostic factors of 104 patients who developed relapse., Results: The 5-year disease-specific overall survival rate was significantly higher in Group B than A (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride, non-clear cell adenocarcinoma and intestinal resection were independent prognostic factors., Conclusions: The induction of new chemotherapeutic drugs and the increased variation of second- or third-line chemotherapy affected the improvement in overall survival of patients with advanced epithelial ovarian cancer., (© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.